Hong Kong Skyline
Nikada | E+ | Getty Pictures
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience firm with no income, is the most recent speculative abroad inventory to draw an uncommon surge in buying and selling demand.
Shares of Regencell, which says it develops conventional Chinese language herb remedies to deal with childhood consideration deficit hyperactivity dysfunction and autism, greater than tripled on Monday — hovering greater than 280% by the shut after a 38-for-1 break up declared on June 2 took impact. By Monday’s shut, Regencell, based in 2014 and traded on Nasdaq beneath the ticker ‘RGC’ since 2021, had a complete market capitalization of $29.7 billion, based on S&P Capital IQ.
The inventory continued to leap on Tuesday, gaining greater than 25%. The corporate’s 12 months thus far efficiency is off the charts too, having risen greater than 58,000% in 2025. Its present market worth of $36 billion tops Lululemon, eBay and Kraft Heinz. The shares traded for pennies at one level up to now one 12 months.
Regencell Bioscience Holdings in 2025.
Regencell is the most recent instance of a speculative worldwide inventory attracting consideration throughout summer time buying and selling. In August, 2022, for instance, AMTD Digital, a Hong Kong-based fintech firm, climbed 126%, briefly giving it a market worth higher than Coca-Cola and Financial institution of America.
Earlier this month, Regencell defined the inventory break up as designed solely “to boost liquidity available in the market for the corporate’s unusual shares and make the shares extra accessible to buyers.” Inventory splits don’t change something essentially about an organization.
Regencell’s surge additionally got here amid an elevated deal with various medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Division of Well being and Human Providers in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations within the U.S., final week eradicating the entire members of a panel that advises the Facilities for Illness Management and Prevention on vaccines.
Regencell’s inventory typically makes large one-day swings. For instance, shares jumped roughly 30% on March 21, earlier than dropping 30% the next buying and selling day.
Obscure remedies, zero income
Despite the wild spike within the inventory, little is thought concerning the efficacy and commercialization of Regencell’s remedies for ADHD and Autistic Spectrum Issues.
Regencell’s enterprise facilities on a proprietary Conventional Chinese language Drugs formulation (TCM) developed in a partnership with TCM practitioner Sik-Kee Au utilizing his “Sik-Kee Au TCM Mind Concept.” Sik-Kee Au is the daddy of the Regencell chief govt officer Yat-Gai Au, the corporate stated in a 2022 assertion.
The CEO controls 86.24% of the full variety of shares excellent, based on FactSet information.
Three liquid-based, orally-taken TCM formulae candidates declare to deal with delicate, reasonable and extreme situations and solely include pure components akin to so-called “detoxication herbs,” blood circulation herbs and digestion herbs.
“These TCM formulae kind the premise of our TCM product candidates, which we intend to develop and commercialize for the remedy of ADHD and ASD,” Regencell’s web site reads.
In its newest annual report filed final October, Regencell stated that it had not generated any income, nor filed for any regulatory approvals of its TCM formulation. For the fiscal years ended June 2024 and 2023, Regencell incurred complete internet losses of $4.36 million and $6.06 million, respectively, based on a submitting to the SEC.
“We’ve not generated income from any TCM formulae candidates or utilized for any regulatory approvals, nor have distribution capabilities or expertise or any granted patents or pending patent functions and will by no means be worthwhile,” learn the submitting.
Regencell has not responded to a CNBC request for remark.
Regencell’s newest affected person case research, dated Nov. 15, 2023, stated 28 sufferers got the remedy over a interval of three months in a second efficacy trial and confirmed an enchancment in signs of ADHD and ASD, based on the corporate’s webpage.
In an earlier case, Regencell stated in a 2021 information launch that it handled a dozen sufferers with suspected or confirmed Covid-19 circumstances, utilizing a modified model of Au’s modified proprietary chilly and flu TCM formulation. What was described as an enchancment of Covid situations led Regencell to kind a three way partnership with Honor Epic Enterprises Restricted in Sept. 2021 to conduct additional exams and commercialize the corporate’s Covid remedy in nations belonging to the Affiliation of Southeast Asian Nations, based on the assertion.
On-line buzz
The inventory has attracted little chatter on social media over the previous few years. These feedback which have been made counsel each retail dealer enthusiasm — and skepticism.
One person on the Reddit web page “r/Shortsqueeze” wrote on Monday that Regencell is “buying and selling like a meme coin. Purchased a bit to see what occurs and it dropped 50% proper after lol.” One other person stated in a submit made three months in the past, “I scalp RGC on a regular basis for a little bit of revenue.” The inventory jumped 1,360% in Might alone.
On LinkedIn in Might, one investor stated he “cannot cease laughing,” after studying the corporate description. One other submit from a person within the pharmaceutical trade, based on his profile, final week stated Regencell has turn out to be the “inventory to look at” after its spike in Might on “no official information or catalysts.” One other LinkedIn person final month commented on Regencell, saying, “China based mostly, low quantity and no official information, bizarro.”
On X, one person wrote in a Monday submit, “for #CompleteBullsh__CompanyOfTheYear I nominate regencell.”
— CNBC’s Scott Schnipper contributed reporting.
